CARMEL, Ind., June 12, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company powering better health by providing meaningful solutions, announced today it has been awarded a contract with the North Carolina Department of Public Safety, Division of Juvenile Justice and Delinquency Prevention to provide statewide nursing services. The contract is effective for one year, with two additional one-year renewal options.
Under the contract, Syra Health will supply temporary nursing staff to Youth Development Centers and Juvenile Detention Centers across North Carolina. The roles include registered nurses, licensed practical nurses, medical technicians, and certified nursing assistants to provide for the medical needs of youth in the custody of the Department of Public Safety. The revenue generated by the contract is based on both the number of positions to be filled and the duration of each.
The Syra Health-provided clinical healthcare staff will be responsible for screening and evaluating youth upon admission, developing healthcare plans, and providing appropriate interventions.
"We are honored to work with government agencies to provide essential healthcare services," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "Our team is committed to delivering the highest quality of care and support across the nation."
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company that is powering better health in challenging areas such as behavioral and mental health, digital health, and population health, by providing innovative and meaningful solutions. Syra Health's offerings are centered on prevention, improved access, and affordable care. Syra Health serves everyone working in healthcare. For more information, visit www.syrahealth.com.
FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.41 |
Daily Change: | -0.05 -9.89 |
Daily Volume: | 178,254 |
Market Cap: | US$3.680M |
December 02, 2024 November 26, 2024 October 29, 2024 September 13, 2024 August 08, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB